Earnings Ahead

ARWR - Arrowhead Research Corp.

23.34 -0.26 -1.1

Arrowhead Research Corp.

Arrowhead Research Corp.

About

Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to


Headquarters

Pasadena, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

ARWR



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Arrowhead Pharmaceuticals GAAP EPS of $0.45 beats by $1.06, revenue of $146.26M beats by $100.78M
  • Arrowhead rises 17% after early data for asthma candidate
  • Arrowhead Pharma surges 16% on positive data from early-stage trial of inflammatory pulmonary diseases therapy
  • What is behind biotech M&A resurgence?
  • Alnylam, Intra-Cellular among potential biotech take-out targets - RBC
  • Arrowhead adds 11% as SVB upgrades on compelling risk-reward setup
  • Arrowhead to get $40M milestone as Takeda starts fazirsiran dosing in liver disease trial
  • Arrowhead stock pops after $30M milestone from GSK under liver drug pact
  • Arrowhead wins FDA Fast Track status for lipid lowering agent
  • Arrowhead's RNAi therapy for complement disorders shows promise in interim trial data
  • J&J returns rights to NASH RNAi candidate to Arrowhead Pharmaceuticals
  • Arrowhead Pharmaceuticals' fiscal 2023 Q1 revenue surge helped by milestone payments
  • Arrowhead Pharmaceuticals EPS of -$0.39, revenue of $62.55M
  • Arrowhead drops as Cantor flags risks to Johnson & Johnson licensing deal
  • Arrowhead Pharmaceuticals Q1 2023 Earnings Preview
  • Arrowhead stock dips ~15% amid phase 2 data for liver disease drug fazirsiran
  • Arrowhead receives $25M milestone payment from Amgen for heart disease treatment
  • Arrowhead Pharmaceuticals GAAP EPS of -$1.67 misses by $0.70, revenue of $243.23M misses by $50.38M
  • Arrowhead Pharmaceuticals Q4 2022 Earnings Preview
  • Earnings week ahead: Salesforce, CrowdStrike, Kroger, Dollar General and more
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
February 2, 2022 -0.6 / -0.4529 27.44M / 47.89M
November 22, 2021 -0.61 / 0.0478 38.29M / 42.19M
August 5, 2021 -0.29 / -0.1378 45.89M / 43.47M Beat!
May 4, 2021 -0.26 / 0.1031 32.81M / 39.42M
February 4, 2021 -0.2 / 0.1213 21.3M / 106.12M
November 23, 2020 -0.48 / 0.0991 7.63M / 57.76M Beat!
August 5, 2020 -0.13 / -0.12 27.38M / 30.42M
May 7, 2020 -0.2 / -0.11 23.53M / 22.16M Beat!
February 5, 2020 -0.03 / 0.02 29.45M / 31.08M
November 25, 2019 0.11 / 0.16 43.29M / 40.98M Beat!
August 5, 2019 0.21 / 0.28 42.7M / 54.37M
May 8, 2019 0.24 / 0.2 48.15M / 42.92M Beat!
February 7, 2019 0.13 / 0.54 34.66M / 71.6M
Date Price Open High Low Vol Change ER
Oct 9, 2023 24.97 24.91
25.1
24.22
591K -0.87%
Oct 6, 2023 25.19 25.25
25.8
25.01
640K -1.41%
Oct 5, 2023 25.55 23.48
25.57
23.44
1.6M 7.49%
Oct 4, 2023 23.77 25.26
25.58
23.63
1.3M -5.52%
Oct 3, 2023 25.16 26.07
26.12
24.65
1.1M -4.15%
 
Oct 2, 2023 26.25 26.52
26.78
25.94
1.3M -2.31%
Sep 29, 2023 26.87 27.13
27.42
26.34
807K -0.22%
Sep 28, 2023 26.93 26.33
27.31
26.04
760K 2.05%
Sep 27, 2023 26.39 26.37
26.66
26.08
667K 0.73%
Sep 26, 2023 26.2 26.75
27.32
26.18
1.1M -1.76%
Sep 25, 2023 26.67 26.98
27.12
26.37
648K -2.09%
Sep 22, 2023 27.24 27.28
27.64
27.04
596K 0.04%
Sep 21, 2023 27.23 26.78
27.63
26.51
790K 0.81%
Sep 20, 2023 27.01 27.25
27.49
26.89
820K -0.81%
Sep 19, 2023 27.23 28.02
28.02
27.16
627K -3.2%
Sep 18, 2023 28.13 28.94
29.05
27.51
931K -2.73%
Sep 15, 2023 28.92 30.59
30.73
28.88
2.4M -5.3%
Sep 14, 2023 30.54 29.55
31.14
29.31
1.3M 4.09%
Sep 13, 2023 29.34 29.11
29.7
29.06
733K 0.82%
Sep 12, 2023 29.1 29.13
29.4
28.56
750K -0.48%
Sep 11, 2023 29.24 30.25
30.58
29.13
1.1M -2.21%
Sep 8, 2023 29.9 30.25
30.7
29.78
723K -1.06%
Sep 7, 2023 30.22 29
30.48
28.82
1.1M 3.42%
Sep 6, 2023 29.22 28.18
29.29
27.73
827K 4.25%
Sep 5, 2023 28.03 27.74
28.51
27.62
685K 0.25%
Sep 1, 2023 27.96 27.78
28.4
27.75
794K 1.16%
Aug 31, 2023 27.64 26.78
28.01
26.78
1.2M 2.98%
Aug 30, 2023 26.84 27.15
27.54
26.76
823K -1.14%
Aug 29, 2023 27.15 27.69
27.69
26.94
1.2M -1.84%
Aug 28, 2023 27.66 27.93
28.13
27.33
675K -0.9%
Aug 25, 2023 27.91 27.85
28.3
26.83
1.1M -0.46%
Aug 24, 2023 28.04 28.63
28.86
27.99
529K -2.03%
Aug 23, 2023 28.62 28.43
29.04
28.43
475K 0.85%
Aug 22, 2023 28.38 28.68
28.9
28.18
635K -1.05%
Aug 21, 2023 28.68 28.26
29.16
27.77
622K 1.49%
Aug 18, 2023 28.26 28.76
29.02
28.24
655K -2.62%
Aug 17, 2023 29.02 28.95
29.18
28.7
527K 0.24%
Aug 16, 2023 28.95 29.26
29.26
28.81
563K -1.36%
Aug 15, 2023 29.35 29.15
29.7
28.92
584K -0.14%
Aug 14, 2023 29.39 28.56
29.73
28
911K 1.87%
Aug 11, 2023 28.85 28.79
29.19
28.56
668K -0.41%
Aug 10, 2023 28.97 29.01
29.37
28.65
686K -0.14%
Aug 9, 2023 29.01 27.5
29.36
27.28
1.5M 5.53%
Aug 8, 2023 27.49 29.63
29.65
26.93
2.7M -10.78%
Aug 7, 2023 30.81 31.65
31.79
30.71
765K -2.65%
Aug 4, 2023 31.65 32.31
32.74
31.57
664K -2.07%
Aug 3, 2023 32.32 32.85
32.92
32.1
674K -1.97%
Aug 2, 2023 32.97 33.26
33.59
32.63
877K -2.11%
Aug 1, 2023 33.68 34.37
34.46
33.52
1.0M -2.43%
Jul 31, 2023 34.52 35.13
35.69
34.35
620K -1.74%
Jul 28, 2023 35.13 36.07
36.2
35.02
599K -1.95%
Jul 27, 2023 35.83 35.34
36.27
35.21
1.3M 2.08%
Jul 26, 2023 35.1 35.69
36
35.05
840K -1.46%
Jul 25, 2023 35.62 34.87
35.69
34.87
677K 1.60%
Jul 24, 2023 35.06 35.99
36.43
34.85
762K -2.83%
Jul 21, 2023 36.08 35.31
36.12
34.84
964K 3.62%
Jul 20, 2023 34.82 34.75
35.4
34.51
674K 0.72%
Jul 19, 2023 34.57 35.25
35.42
34.27
515K -1.2%
Jul 18, 2023 34.99 34.7
35.17
34.58
662K 0.84%
Jul 17, 2023 34.7 34.4
35.7
34.4
1.2M 0%